When Does Xtandi's Patent Expiry Date?
Xtandi, a medication used to treat prostate cancer, is a prescription drug developed by Medivation and Astellas Pharma. According to DrugPatentWatch.com [1], Xtandi's patent expiry dates vary by country, but the key dates to note are:
* In the United States, xtandi is covered by US patents 9,273,133, 9,273,134, and 10,033,842, set to expire on [2025], [2027], and [2028] respectively [1].
What Happens When Xtandi's Patent Expiry Date Arrives?
After Xtandi's patent expiry date, generic versions of the drug may be approved for the US market. This typically involves a generic company filing for approval with the FDA, followed by a review process [2].
Impact on Xtandi's Price
Generic versions of Xtandi are likely to lower the treatment cost for prostate cancer patients in the United States, as they enter the market. A lower price could make Xtandi more accessible to patients and may affect the sales of the branded version.
What Is the Competition in Prostate Cancer Treatment?
The market for prostate cancer treatment is highly competitive, with medications such as Zytiga and Jevtana also available. Xtandi's patent expiry may lead to increased competition from generic versions, which could lead to a wider range of treatment options for patients.
However, the exact impact of Xtandi's patent expiry and any potential generic competition will depend on multiple factors, including future patent decisions and the market dynamics of the prostate cancer treatment landscape.
Sources:
[1] DrugPatentWatch.com – (https://www.drugpatentwatch.com/drug/xtandi#patents)
[2] US FDA - (https://www.fda.gov/drugs/new-drug-approvals-new-indications-drug-product-classifications/new-drug-approval-process)